Harnessing Apoptosis for Improved Anticancer Gene Therapy

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8563-8572

  Waxman, David J ^a   Schwartz, Pamela S ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOTOXIC AGENT; DRUG METABOLITE; PRODRUG; PROTEIN P35;

ANIMAL; APOPTOSIS; CANCER RESISTANCE; CANCER THERAPY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; MITOCHONDRION; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIZATION; SUICIDE GENE THERAPY; TUMOR CELL;

ANIMALS; APOPTOSIS; DNA DAMAGE; GENE THERAPY; HUMANS; NEOPLASMS;

EID: 0346059610     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Ding, H. F., and Fisher, D. E. Induction of apoptosis in cancer: new therapeutic opportunities. Ann. Med., 34: 451-469, 2002.
2. Zornig, M., Hueber, A., Baum, W., and Evan, G. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta, 1551: F1-F37, 2001.
3. Nunez, G., Benedict, M. A., Hu, Y., and Inohara, N. Caspases: the proteases of the apoptotic pathway. Oncogene, 17: 3237-3245, 1998.
4. Chen, M., and Wang, J. Initiator caspases in apoptosis signaling pathways. Apoptosis, 7: 313-319, 2002.
5. Thornberry, N. A., and Lazebnik, Y. Caspases: enemies within. Science (Wash. DC), 281: 1312-1316, 1998.
6. Green, D. R. Apoptotic pathways: paper wraps stone blunts scissors. Cell, 102: 1-4, 2000.
7. Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.
8. Green, D. R. Apoptotic pathways: the roads to ruin. Cell, 94: 695-698, 1998.
9. Ashkenazi, A., and Dixit, V. M. Death receptors: signaling and modulation. Science (Wash. DC), 281: 1305-1308, 1998.
10. van Loo, G., Saelens, X., van Gurp, M., MacFarlane, M., Martin, S. J., and Vandenabeele, P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ., 9: 1031-1042, 2002.
11. Lemasters, J. J., Qian, T., He, L., Kim, J. S., Elmore, S. P., Cascio, W. E., and Brenner, D. A. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid. Redox Signal, 4: 769-781, 2002.
12. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC), 281: 1309-1312, 1998.
13. Slee, E. A., Harte, M. T., Kluck, R. M., Wolf, B. B., Casiano, C. A., Newmeyer, D. D., Wang, H. G., Reed, J. C., Nicholson, D. W., Alnemri, E. S., Green, D. R., and Martin, S. J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol., 144: 281-292, 1999.
14. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Brenner, C., Larochette, N., Prevost, M. C., Alzari, P. M., and Kroemer, G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med., 189: 381-394, 1999.
15. Joza, N., Susin, S. A., Daugas, E., Stanford, W. L., Cho, S. K., Li, C. Y., Sasaki, T., Elia, A. J., Cheng, H. Y., Ravagnan, L., Ferri, K. F., Zamzami, N., Wakeham, A., Hakem, R., Yoshida, H., Kong, Y. Y., Mak, T. W., Zuniga-Pflucker, J. C., Kroemer, G., and Penninger, J. M. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (Lond.), 410: 549-554, 2001.
16. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factor [see comments]. Nature (Lond.), 397: 441-446, 1999.
17. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 102: 43-53, 2000.
18. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102: 33-42, 2000.
19. Salvesen, G. S., and Duckett, C. S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol., 3: 401-410, 2002.
20. Chinnaiyan, A. M. The apoptosome: heart and soul of the cell death machine. Neoplasia, 1: 5-15, 1999.
21. Cain, K., Bratton, S. B., and Cohen, G. M. The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie, 84: 203-214, 2002.
22. Reed, J. C. Bcl-2 family proteins. Oncogene, 17: 3225-3236, 1998.
23. Baker, S. J., and Reddy, E. P. Modulation of life and death by the TNF receptor superfamily. Oncogene, 17: 3261-3270, 1998.
24. Micheau, O., Solary, E., Hammann, A., and Dimanche-Boitrel, M. T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem., 274: 7987-7992, 1999.
25. Tibbetts, M. D., Zheng, L., and Lenardo, M. J. The death effector domain protein family: regulators of cellular homeostasis. Nat. Immunol., 4: 404-409, 2003.
26. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.
27. Tang, D., Lahti, J. M., and Kidd, V. J. Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J. Biol. Chem., 275: 9303-9307, 2000.
28. Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S. J., Krammer, P. H., and Peter, M. E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 274: 22532-22538, 1999.
29. Kuwana, T., Smith, J. J., Muzio, M., Dixit, V., Newmeyer, D. D., and Kornbluth, S. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J. Biol. Chem., 273: 16589-16594, 1998.
30. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q., Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J., 17: 2215-2223, 1998.
31. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer, 3: 46-54, 2003.
32. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., and Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (Wash. DC), 288: 874-877, 2000.
33. Ashkenazi, A., and Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 11: 255-260, 1999.
34. Sheikh, M. S., and Fornace, A. J., Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia (Baltimore), 14: 1509-1513, 2000.
35. Pitti, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kischkel, F. C., Dowd, P., Huang, A., Donahue, C. J., Sherwood, S. W., Baldwin, D. T., Godowski, P. J., Wood, W. I., Gurney, A. L., Hillan, K. J., Cohen, R. L., Goddard, A. D., Botstein, D., and Ashkenazi, A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (Lond.), 396: 699-703, 1998.
36. Connolly, K., Cho, Y. H., Duan, R., Fikes, J., Gregorio, T., LaFleur, D. W., Okoye, Z., Salcedo, T. W., Santiago, G., Ullrich, S., Wei, P., Windle, K., Wong, E., Yao, X. T., Zhang, Y. Q., Zheng, G., and Moore, P. A. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J. Pharmacol. Exp. Ther., 298: 25-33, 2001.
37. van Noesel, M. M., van Bezouw, S., Salomons, G. S., Voute, P. A., Pieters, R., Baylin, S. B., Herman, J. G., and Versteeg, R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res., 62: 2157-2161, 2002.
38. Zhang, X. D., Nguyen, T., Thomas, W. D., Sanders, J. E., and Hersey, P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett., 482: 193-199, 2000.
39. Bradley, J. R., and Pober, J. S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene, 20: 6482-6491, 2001.
40. Gupta, S. A decision between life and death during TNF-α-induced signaling. J. Clin. Immunol., 22: 185-194, 2002.
41. Barkett, M., and Gilmore, T. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene, 18: 6910-6924, 1999.
42. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (Wash. DC), 281: 1680-1683, 1998.
43. Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., and Lin, A. Inhibition of JNK activation through NF-KB target genes. Nature (Lond.), 414: 313-317, 2001.
44. Bernard, D., Quatannens, B., Vandenbunder, B., and Abbadie, C. Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J. Biol. Chem., 276: 27322-27328, 2001.
45. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. NF-κB signals induce the expression of c-FLIP. Mol. Cell. Biol., 21: 5299-5305, 2001.
46. Wang, C. Y., Guttridge, D. C., Mayo, M. W., and Baldwin, A. S., Jr. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol., 19: 5923-5929, 1999.
47. Li, X., Yang, Y., and Ashwell, J. D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature (Lond.), 416: 345-347, 2002.
48. Sellers, W. R., and Fisher, D. E. Apoptosis and cancer drug targeting. J. Clin. Investig., 104: 1655-1661, 1999.
49. Papaconstantinou, H. T., Xie, C., Zhang, W., Ansari, N. H., Hellmich, M. R., Townsend, C. M., Jr., and Ko, T. C. The role of caspases in methotrexate-induced gastrointestinal toxicity. Surgery, 130: 859-865, 2001.
50. Fulda, S., Susin, S. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998.
51. Schwartz, P. S., and Waxman, D. J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol., 60: 1268-1279, 2001.
52. Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and Green, D. R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell, 1: 543-551, 1998.
53. Tillman, D. M., Petak, I., and Houghton, J. A. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res., 5: 425-430, 1999.
54. Adachi, Y., Taketani, S., Oyaizu, H., Ikebukuro, K., Tokunaga, R., and Ikehara, S. Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8. Int. J. Oncol., 15: 1191-1196, 1999.
55. Stahnke, K., Fulda, S., Friesen, C., Strauss, G., and Debatin, K. M. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood, 98: 3066-3073, 2001.
56. Seki, K., Yoshikawa, H., Shiiki, K., Hamada, Y., Akamatsu, N., and Tasaka, K. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8,-3 and -6 in osteosarcoma. Cancer Chemother. Pharmacol., 45: 199-206, 2000.
57. Ofir, R., Seidman, R., Rabinski, T., Krup, M., Yavelsky, V., Weinstein, Y., and Wolfson, M. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ., 9: 636-642, 2002.
58. Yuan, S. Y., Hsu, S. L., Tsai, K. J., and Yang, C. R. Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells. Urol. Res., 30: 282-288, 2002.
59. Beltinger, C., Fulda, S., Kammertoens, T., Meyer, E., Uckert, W., and Debatin, K. M. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA, 96: 8699-8704, 1999.
60. Tomicic, M. T., Thust, R., and Kaina, B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene, 21: 2141-2153, 2002.
61. von Haefen, C., Wieder, T., Essmann, F., Schulze-Osthoff, K., Dorken, B., and Daniel, P. T. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene, 22: 2236-2247, 2003.
62. Huisman, C., Ferreira, C. G., Broker, L. E., Rodriguez, J. A., Smit, E. F., Postmus, P. E., Kruyt, F. A., and Giaccone, G. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NC1-H460. Clin. Cancer Res., 8: 596-606, 2002.
63. Obrero, M., Yu, D. V., and Shapiro, D. J. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J. Biol. Chem., 277: 45695-45703, 2002.
64. Van Den Bosch, M., Bree, R. T., and Lowndes, N. F. The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep., 4: 844-849, 2003.
65. Fei, P., and El-Deiry, W. S. p53 and radiation responses. Oncogene, 22: 5774-5783, 2003.
66. Iliakis, G., Wang, Y., Guan, J., and Wang, H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene, 22: 5834-5847, 2003.
67. 2 phase DNA double-strand break repair. J. Biol. Chem., 276: 44413-44418, 2001.
68. Kharbanda, S., Yuan, Z. M., Weichselbaum, R., and Kufe, D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene, 17: 3309-3318, 1998.
69. Yuan, L., Yu, W. M., Yuan, Z., Haudenschild, C. C., and Qu, C. K. Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response. J. Biol. Chem., 278: 15208-15216, 2003.
70. Meek, D. W. Mechanisms of switching on p53: a role for covalent modification? Oncogene, 18: 7666-7675, 1999.
71. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M., and Wang, J. Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (Lond.), 399: 806-809, 1999.
72. Agami, R., Blandino, G., Oren, M., and Shaul, Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature (Lond.), 399: 809-813, 1999.
73. Lin, W. C., Lin, F. T., and Nevins, J. R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev., 15: 1833-1844, 2001.
74. Achanta, G., Pelicano, H., Feng, L., Plunkett, W., and Huang, P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res., 61: 8723-8729, 2001.
75. Gartel, A. L., and Tyner, A. L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther., 1: 639-649, 2002.
76. Rich, T., Allen, R. L., and Wyllie, A. H. Defying death after DNA damage. Nature (Lond.), 407: 777-783, 2000.
77. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science (Wash. DC), 288: 1053-1058, 2000.
78. Schuler, M., Maurer, U., Goldstein, J. C., Breitenbucher, F., Hoffarth, S., Waterhouse, N. J., and Green, D. R. p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ., 10: 451-460, 2003.
79. Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., and Zhang, L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. USA, 100: 1931-1936, 2003.
80. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56: 556-562, 1996.
81. Findley, H. W., Gu, L., Yeager, A. M., and Zhou, M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood, 89: 2986-2993, 1997.
82. Donald, S. P., Sun, X. Y., Hu, C. A., Yu, J., Mei, J. M., Valle, D., and Phang, J. M. Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res., 61: 1810-1815, 2001.
83. Maxwell, S. A., and Rivera, A. Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinomas. J. Biol. Chem., 278: 9784-9789, 2003.
84. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.
85. Raina, D., Mishra, N., Kumar, S., Kharbanda, S., Saxena, S., and Kufe, D. Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-β -D-arabinofuranosylcytosine. Mol. Pharmacol., 61: 1489-1495, 2002.
86. Blattner, C., Sparks, A., and Lane, D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol., 19: 3704-3713, 1999.
87. Pediconi, N., Ianari, A., Costanzo, A., Belloni, L., Gallo, R., Cimino, L., Porcellini, A., Screpanti, I., Balsano, C., Alesse, E., Gulino, A., and Levrero, M. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol., 5: 552-558, 2003.
88. Moroni, M. C., Hickman, E. S., Denchi, E. L., Caprara, G., Colli, E., Cecconi, F., Muller, H., and Helin, K. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol., 3: 552-558, 2001.
89. Furukawa, Y., Nishimura, N., Satoh, M., Endo, H., Iwase, S., Yamada, H., Matsuda, M., Kano, Y., and Nakamura, M. Apaf-1 is a mediator of E2F-1-induced apoptosis. J. Biol. Chem., 277: 39760-39768, 2002.
90. Nahle, Z., Polakoff, J., Davuluri, R. V., McCurrach, M. E., Jacobson, M. D., Narita, M., Zhang, M. Q., Lazebnik, Y., Bar-Sagi, D., and Lowe, S. W. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol., 4: 859-864, 2002.
91. Croxton, R., Ma, Y., Song, L., Haura, E. B., and Cress, W. D. Direct repression of the Mcl-1 promoter by E2F1. Oncogene, 21: 1359-1369, 2002.
92. Wang, J. Y., and Ki, S. W. Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem. Soc. Trans., 29: 666-673, 2001.
93. Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. G. Chemosensitivity linked to p73 function. Cancer Cell, 3: 403-410, 2003.
94. Ben-Yehoyada, M., Ben-Dor, I., and Shaul, Y. c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J. Biol. Chem., 278: 34475-34482, 2003.
95. Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., Balsano, C., and Levrero, M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell., 9: 175-186, 2002.
96. Tsai, K. K., and Yuan, Z. M. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res., 63: 3418-3424, 2003.
97. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
98. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
99. Wu, G. S., Burns, T. F., McDonald, E. R., III, Meng, R. D., Kao, G., Muschel, R., Yen, T., and el-Deiry, W. S. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene, 18: 6411-6418, 1999.
100. Nagane, M., Pan, G., Weddle, J. J., Dixit, V. M., Cavenee, W. K., and Huang, H. J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res., 60: 847-853, 2000.
101. Eichhorst, S. T., Muller, M., Li-Weber, M., Schulze-Bergkamen, H., Angel, P., and Krammer, P. H. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol., 20: 7826-7837, 2000.
102. Mow, B. M., Blajeski, A. L., Chandra, J., and Kaufmann, S. H. Apoptosis and the response to anticancer therapy. Curr. Opin. Oncol., 13: 453-462, 2001.
103. Petak, I., and Houghton, J. A. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol. Oncol. Res., 7: 95-106, 2001.
104. Petak, I., Tillman, D. M., Harwood, F. G., Mihalik, R., and Houghton, J. A. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res., 60: 2643-2650, 2000.
105. Kinoshita, H., Yoshikawa, H., Shiiki, K., Hamada, Y., Nakajima, Y., and Tasaka, K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int. J. Cancer, 88: 986-991, 2000.
106. Swisher, S. G., and Roth, J. A. Clinical update of Ad-p53 gene therapy for lung cancer. Surg. Oncol. Clin. N. Am., 11: 521-535, 2002.
107. Reed, J. C. Apoptosis-based therapies. Nat. Rev. Drug Discov., 11: 111-121, 2002.
108. Lane, D. P., and Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med., 8: S38-S42, 2002.
109. Fueyo, J., Gomez-Manzano, C., Yung, W. K., Liu, T. J., Alemany, R., McDonnell, T. J., Shi, X., Rao, J. S., Levin, V. A., and Kyritsis, A. P. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med., 4: 685-690, 1998.
110. Dong, Y. B., Yang, H. L., Elliott, M. J., and McMasters, K. M. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res., 62: 1776-1783, 2002.
111. Kim, R., Tanabe, K., Erni, M., Uchida, Y., Inoue, H., and Toge, T. Inducing cancer cell death by targeting transcription factors. Anticancer Drugs, 14: 3-11, 2003.
112. Deng, J., Xia, W., and Hung, M. C. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene, 17: 2167-2175, 1998.
113. Nettelbeck, D. M., Rivera, A. A., Balague, C., Alemany, R., and Curiel, D. T. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res., 62: 4663-4670, 2002.
114. Yamabe, K., Shimizu, S., Ito, T., Yoshioka, Y., Nomura, M., Narita, M., Saito, I., Kanegae, Y., and Matsuda, H. Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther., 6: 1952-1959, 1999.
115. Marcelli, M., Cunningham, G. R., Walkup, M., He, Z., Sturgis, L., Kagan, C., Mannucci, R., Nicoletti, I., Teng, B., and Denner, L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res., 59: 382-390, 1999.
116. Mesri, M., Wall, N. R., Li, J., Kim, R. W., and Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Investig., 108: 981-990, 2001.
117. Perkins, C. L., Fang, G., Kim, C. N., and Bhalla, K. N. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res., 60: 1645-1653, 2000.
118. Kagawa, S., Gu, J., Swisher, S. G., Ji, L., Roth, J. A., Lai, D., Stephens, L. C., and Fang, B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res., 60: 1157-1161, 2000.
119. Kaliberov, S. A., Buchsbaum, D. J., Gillespie, G. Y., Curiel, D. T., Arafat, W. O., Carpenter, M., and Stackhouse, M. A. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol. Ther., 6: 190-198, 2002.
120. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., and Cotter, F. E. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 18: 1812-1823, 2000.
121. Klasa, R. J., Bally, M. B., Ng, R., Goldie, J. H., Gascoyne, R. D., and Wong, F. M. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res., 6: 2492-2500, 2000.
122. Zangemeister-Wittke, U., Leech, S. H., Olie, R. A., Simoes-Wust, A. P., Gautschi, O., Luedke, G. H., Natt, F., Haner, R., Martin, P., Hall, J., Nalin, C. M., and Stahel, R. A. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res., 6: 2547-2555, 2000.
123. Piche, A., Grim, J., Rancourt, C., Gomez-Navarro, J., Reed, J. C., and Curiel, D. T. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res., 58: 2134-2140, 1998.
124. Jiang, M., and Milner, J. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev., 17: 832-837, 2003.
125. Tzung, S. P., Kim, K. M., Basanez, G., Giedt, C. D., Simon, J., Zimmerberg, J., Zhang, K. Y., and Hockenbery, D. M. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol., 3: 183-191, 2001.
126. Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., and Yuan, J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol., 3: 173-182, 2001.
127. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Investig., 104: 155-162, 1999.
128. Kagawa, S., He, C., Gu, J., Koch, P., Rha, S. J., Roth, J. A., Curley, S.-A., Stephens, L. C., and Fang, B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res., 61: 3330-3338, 2001.
129. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., and Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res., 59: 734-741, 1999.
130. Cuello, M., Ettenberg, S. A., Nau, M. M., and Lipkowitz, S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol., 81: 380-390, 2001.
131. Daniel, P. T., Wieder, T., Sturm, I., and Schulze-Osthoff, K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia (Baltimore), 15: 1022-1032, 2001.
132. Huang, X., Lin, T., Gu, J., Zhang, L., Roth, J. A., Stephens, L. C., Yu, Y., Liu, J., and Fang, B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther., 9: 1379-1386, 2002.
133. Kim, K., Takimoto, R., Dicker, D. T., Chen, Y., Gazitt, Y., and El-Deiry, W. S. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int. J. Oncol., 18: 241-247, 2001.
134. Fulda, S., Wick, W., Weller, M., and Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 8: 808-815, 2002.
135. Ng, C. P., and Bonavida, B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther., 1: 1051-1058, 2002.
136. Guo, F., Nimmanapalli, R., Paranawithana, S., Wittman, S., Griffin, D., Bali, P., O'Bryan, E., Fumero, C., Wang, H. G., and Bhalla, K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood, 99: 3419-3426, 2002.
137. Weaver, K. D., Yeyeodu, S., Cusack, J. C., Jr., Baldwin, A. S., Jr., and Ewend, M. G. Potentiation of chemotherapeutic agents following antagonism of nuclear factor-κB in human gliomas. J. Neurooncol., 61: 187-196, 2003.
138. Chen, S., Fribley, A., and Wang, C. Y. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-κB inhibitor. J. Dent. Res., 81: 98-102, 2002.
139. Tietze, M. K., Wuestefeld, T., Paul, Y., Zender, L., Trautwein, C., Manns, M. P., and Kubicka, S. IκBα gene therapy in tumor necrosis factor-α- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther., 7: 1315-1323, 2000.
140. Adams, J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov. Today, 8: 307-315, 2003.
141. Cheson, B. D. Hematologic malignancies: new developments and future treatments. Semin. Oncol., 29: 33-45, 2002.
142. Biswas, D. K., Martin, K. J., McAlister, C., Cruz, A. P., Graner, E., Dai, S. C., and Pardee, A. B. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-κB activation. Cancer Res., 63: 290-295, 2003.
143. Springer, C. J., and Niculescu-Duvaz, I. Prodrug-activating systems in suicide gene therapy. J. Clin. Investig., 105: 1161-1167, 2000.
144. Chen, L., and Waxman, D., J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharmaceut. Design, 8: 1405-1416, 2002.
145. Pope, I. M., Poston, G. J., and Kinsella, A. R. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer, 33: 1005-1016, 1997.
146. Sturtz, F. G., Waddell, K., Shulok, J., Chen, X., Caruso, M., Sanson, M., Snodgrass, H. R., and Platika, D. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy. Hum. Gene Ther., 8: 1945-1953, 1997.
147. Moolten, F. L., and Wells, J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst., 82: 297-300, 1990.
148. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res., 54: 1503-1506, 1994.
149. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
150. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K. H., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakefield, X. O., and Chiocca, E. A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther., 5: 969-978, 1994.
151. Chen, L., and Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
152. Jounaidi, Y., and Waxman, D. J. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res., 60: 3761-3769, 2000.
153. McCarthy, H. O., Yakkundi, A., McErlane, V., Hughes, C. M., Keilty, G., Murray, M., Patterson, L. H., Hirst, D. G., McKeown, S. R., and Robson, T. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther., 10: 40-48, 2003.
154. Chen, L., Waxman, D. J., Chen, D., and Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res., 56: 1331-1340, 1996.
155. Jounaidi, Y., Hecht, J. E., and Waxman, D. J. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res., 58: 4391-4401, 1998.
156. Jounaidi, Y., and Waxman, D. J. Frequent, moderate dose cyclophosphamide administration improves the efficacy of P450/P450 reductase-based cancer gene therapy. Cancer Res., 61: 4437-4444, 2001.
157. Kan, O., Griffiths, L., Baban, D., Iqball, S., Uden, M., Spearman, H., Slingsby, J., Price, T., Esapa, M., Kingsman, S., Kingsman, A., Slade, A., and Naylor, S. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther., 8: 473-482, 2001.
158. Muller, P., Jesnowski, R., Karle, P., Renz, R., Saller, R., Stein, H., Puschel, K., von Rombs, K., Nizze, H., Liebe, S., Wagner, T., Gunzburg, W. H., Salmons, B., and Lohr, M. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Ann. NY Acad. Sci., 880: 337-351, 1999.
159. Ichikawa, T., Petros, W. P., Ludeman, S. M., Fangmeier, J., Hochberg, F. H., Colvin, O. M., and Chiocca, E. A. Intraneoplastic polymer-based delivery of
160. Pawlik, T. M., Nakamura, H., Mullen, J. T., Kasuya, H., Yoon, S. S., Chandrasekhar, S., Chiocca, E. A., and Tanabe, K. K. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer (Phila.), 95: 1171-1181, 2002.
161. Aghi, M., Chou, T. C., Suling, K., Breakefield, X. O., and Chiocca, E. A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res., 59: 3861-3865, 1999.
162. Jounaidi, Y., and Waxman, D. J. Use of replication-conditional adenovirus as a helper system for enhanced delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res., 64: January, in press, 2004.
163. Kan, O., Kingsman, S., and Naylor, S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin. Biol. Ther., 2: 857-868, 2002.
164. Lohr, M., Hoffmeyer, A., Kroger, J., Freund, M., Hain, J., Holle, A., Karle, P., Knofel, W. T., Liebe, S., Muller, P., Nizze, H., Renner, M., Saller, R. M., Wagner, T., Hauenstein, K., Gunzburg, W. H., and Salmons, B. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet, 357: 1591-1592, 2001.
165. Lohr, M., Hummel, F., Faulmann, G., Ringel, J., Saller, R., Hain, J., Gunzburg, W. H., and Salmons, B. Microencapsulated, CYP2BI-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother. Pharmacol., 49 Suppl 1: S21-S24, 2002.
166. Schwartz, P. S., Chen, C. S., and Waxman, D. J. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Res., 62: 6928-6937, 2002.
167. Gamcsik, M. P., Dolan, M. E., Andersson, B. S., and Murray, D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr. Pharmaceut. Design, 5: 587-605, 1999.
168. Chen, G., and Waxman, D. J. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem. Pharmacol., 47: 1079-1087, 1994.
169. Waxman, D. J. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy: a review. Cancer Res., 50: 6449-6454, 1990.
170. Sladek, N. E. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr. Pharmaceut. Design, 5: 607-625, 1999.
171. Chen, G., and Waxman, D. J. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol., 49: 1691-1701, 1995.
172. Yang, W. Z., Begleiter, A., Johnston, J. B., Israels, L. G., and Mowat, M. R. Role of glutathione and glutathione S-transferase in chlorambucil resistance. Mol. Pharmacol., 41: 625-630, 1992.
173. Puchalski, R. B., and Fahl, W. E. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 2443-2447, 1990.
174. Clem, R. J., and Miller, L. K. Control of programmed cell death by the baculovirus genes p35 and iap. Mol. Cell. Biol., 14: 5212-5222, 1994.
175. Hersey, P., and Zhang, X. D. Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol., 196: 9-18, 2003.
176. Lock, R. B., and Stribinskiene, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res., 56: 4006-4012, 1996.
177. Yin, D. X., and Schimke, R. T. Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res., 55: 4922-4928, 1995.
178. Breton, C., Story, M. D., and Meyn, R. E. Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide. Anticancer Drugs, 9: 751-757, 1998.
179. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 16: 6914-6925, 1997.
180. Xue, L., Fletcher, G. C., and Tolkovsky, A. M. Mitochondria are selectively eliminated from eukaryotic cells after blockade of caspases during apoptosis. Curr. Biol., 11: 361-365, 2001.
181. Amarante-Mendes, G. P., Finucane, D. M., Martin, S. J., Cotter, T. G., Salvesen, G. S., and Green, D. R. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell Death Differ., 5: 298-306, 1998.
182. Brunet, C. L., Gunby, R. H., Benson, R. S., Hickman, J. A., Watson, A. J., and Brady, G. Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death Differ., 5: 107-115, 1998.
183. Joseph, B., Marchetti, P., Formstecher, P., Kroemer, G., Lewensohn, R., and Zhivotovsky, B. Mitochondrial dysfunction is an essential step for killing of nonsmall cell lung carcinomas resistant to conventional treatment. Oncogene, 21: 65-77, 2002.
184. Lawrence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., Trosko, J. E., and Stetson. P. L. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res., 58: 2588-2593, 1998.
185. Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., and Martelli, A. M. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIP(L) up-regulation. Leukemia (Baltimore), 17: 379-389, 2003.
186. Xiao, C. W., Yan, X., Li, Y., Reddy, S. A., and Tsang, B. K. Resistance of human ovarian cancer cells to tumor necrosis factor a is a consequence of nuclear factor-κB-mediated induction of Fas-associated death domain-like interleukin-1β-converting enzyme-like inhibitory protein. Endocrinology, 144: 623-630, 2003.
187. Visted, T., Bjerkvig, R., and Enger, P. O. Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neurooncol., 3: 201-210, 2001.
188. de Felipe, P. Polycistronic viral vectors. Curr. Gene Ther., 2: 355-378, 2002.
189. Mizuguchi, H., and Hayakawa, T. The tet-off system is more effective than the tet-on system for regulating transgene expression in a single adenovirus vector. J. Gene Med., 4: 240-247, 2002.
190. Mayford, M., Bach, M. E., Huang, Y. Y., Wang, L., Hawkins, R. D., and Kandel, E. R. Control of memory formation through regulated expression of a CaMKII transgene. Science (Wash. DC), 274: 1678-1683, 1996.
191. Bohl, D., Naffakh, N., and Heard, J. M. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat. Med., 3: 299-305, 1997.